Literature DB >> 8885332

The autoxidation of the reduced forms of EO9.

J Butler1, V J Spanswick, J Cummings.   

Abstract

The properties of the semiquinone radical from [3-hydroxy-5-aziridinyl-1-methyl-2-(1H-indole-4,7-indi one)-prop-beta-en-alpha-ol], EO9, have been studied using pulse-radiolysis techniques. The reduction potential of the semiquinone of EO9 at pH7.4, E(EO9/EO9-), is -253 +/- 6 mV and hence this quinone can be readily reduced by one-electron reducing enzymes such as cytochrome P450 reductase and xanthine oxidase. However, the radical is unstable in the presence of oxygen (k = 1.3 +/- 0.15 x 10(8) M-1 s-1). The semiquinone radicals and the hydroquinone are in equilibrium although the formation of the hydroquinone is favoured t physiologically relevant pH. The hydroquinone of EO9 is also unstable in the presence of oxygen and it is predicted that in fully aerated solutions, its half life is 1.5 +/- 0.3 seconds. These results are discussed in view of the selective cytotoxicity of EO9 and its ability to undergo bioreductive activation by one-electron reducing enzymes and DT-diaphorase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8885332     DOI: 10.3109/10715769609149919

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  4 in total

Review 1.  EO9 (Apaziquone): from the clinic to the laboratory and back again.

Authors:  Roger M Phillips; Hans R Hendriks; Godefridus J Peters
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

2.  Nitroxides as antioxidants: Tempol protects against EO9 cytotoxicity.

Authors:  Ayelet M Samuni; William DeGraff; Murali C Krishna; James B Mitchell
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

3.  A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9.

Authors:  G A Choudry; P A Stewart; J A Double; M R Krul; B Naylor; G M Flannigan; T K Shah; J E Brown; R M Phillips
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

4.  Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways.

Authors:  S J Allison; J R P Knight; C Granchi; R Rani; F Minutolo; J Milner; R M Phillips
Journal:  Oncogenesis       Date:  2014-05-12       Impact factor: 7.485

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.